Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial-Reference-Cited by-同舟云学术

Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

Published:2017-11-22 Issue:1 Volume:57 Page:26-30
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Jensen Maj-Britt¹,Krarup Jens Fabricius¹,Palshof Torben,Mouridsen Henning T.¹,Ejlertsen Bent¹²

Affiliation:

1. Danish Breast Cancer Cooperative Group (DBCG), Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

2. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2017.1400179

Reference26 articles.

1. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

2. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial

3. Treatment of Primary Breast Cancer with Chemotherapy and Tamoxifen

4. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproductive expression dynamics and comparative toxicological perspective of beta estrogen receptor gene in the male wall lizard, Podarcis sicula Rafinesque, 1810 (Chordata: Reptilia);The European Zoological Journal;2018-01-01

2. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration;Acta Oncologica;2017-12-05